Affiliation:
1. Department of Pharmacology, Fujigotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Komakado, Gotemba, Shizuoka 412, Japan
Abstract
Abstract
The effect of a new orally active angiotensin converting enzyme (ACE) inhibitor, calcium (—)-N-[(S)-3–[(N-cyclohexylcarbonyl-D -alanyl)thio]-2-methylpropionyl]-L -prolinate (MC-838, altiopril calcium), on systemic blood pressure (SBP) and tissue ACE activity has been examined in conscious spontaneously hypertensive rats (SHRs). MC-838 (3 mg kg−1) given orally to SHRs elicited a long-lasting hypotension lasting over 24 h. With the development of the hypotension, MC-838 significantly reduced ACE activity in the lung, kidney and aorta, but not in the brain and heart. Suppression of plasma ACE and rise of plasma renin activity occurred only transiently at an earlier stage.
Publisher
Oxford University Press (OUP)
Subject
Pharmaceutical Science,Pharmacology
Reference8 articles.
1. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with Captopril;Aono;Arch. Int. Pharmacodyn.,1988
2. Circulating and tissue angiotensin system;Campbell;J. Clin. Invest.,1987
3. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with Captopril or MK-421;Cohen;J. Pharmacol. Exp. Ther.,1982
4. Significance of the vascular renin-angiotensin pathway;Dzau;Hypertension.,1986
5. MC-838 (altiopril calcium): a novel orally active angiotensin converting enzyme inhibitor;Sakai;Tohoku J. Exp. Med.,1987
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献